Last month, DIA teamed up with the FDA and Hearth Rhythm Society to present a meeting on Cardiovascular Safety and State-of-the-Art Development Issues: Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity (Apr 17 2012 8:00AM - Apr 18 2012 5:00PM at the Washington Marriott Hotel)
Designed to improve pharmaceutical and medical product development by analyzing and mitigating potential risks, participants had the opportunity to:
- Learn how to optimize cardiovascular (CV) safety assessments in the hopes of developing more effective medications to treat type 2 diabetes mellitus and other diseases
- Attend plenary sessions and select from two tracks on diabetes and CV safety
- Participate in debate-style presentations
- Interact with FDA and other regulatory officials
- Attend scientific abstract presentations
- Engage in robust networking opportunities
Several of the presentations are available on the FDA website.
CDER professionals participate in several meetings, conferences and workshops throughout the year. Appealing primarily to the pharmaceutical industry and health care professionals, topics can range from users fees, to drug advertising and marketing, to genomics, to over-the-counter products. Materials and overviews from some of those meetings are listed in the presentations library.
Deputy Director, Regulatory Programs, Office of the Center Director, CDER
FDA, United States
Integrating Patient Preferences into Benefit-Risk Analysis
Robert J. Temple, MD
Deputy Center Director for Clinical Science, CDER
FDA, United States
Balance on CV SafetyDo We Have It Right?
Robert J. Temple, MD
Deputy Center Director for Clinical Science, CDER
FDA, United States
For the full listing of CDER FDA presentations, please visit this link
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm074833.htm
No comments:
Post a Comment